Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | An overview of daratumumab monotherapy for heavily treated multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, summarises the potential of the anti-CD38 monoclonal antibody, daratumumab, as a novel, well-tolerated, single-agent therapy for patients with heavily treated multiple myeloma.